Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 23 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
- 07 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as per ClinicalTrials.gov record.
- 07 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.